Allantoin

Allantoin is a skin conditioning agent that promotes healthy skin, stimulates new and healthy tissue growth.

Product information

CAS Number: 97-59-6

Molecular Weight: 158.12

Formula: C4H6N4O3

Chemical Name: (2,5-dioxoimidazolidin-4-yl)urea

Smiles: NC(=O)NC1NC(=O)NC1=O

InChiKey: POJWUDADGALRAB-UHFFFAOYSA-N

InChi: InChI=1S/C4H6N4O3/c5-3(10)6-1-2(9)8-4(11)7-1/h1H,(H3,5,6,10)(H2,7,8,9,11)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 50 mg/mL (316.22 mM; Need ultrasonic). H2O : 3.85 mg/mL (24.35 mM; Need ultrasonic).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Allantoin is a well-known cosmetic ingredient reported to have anti-oxidative and anti-inflammatory activities. Allantoin attenuates apoptosis and cytotoxicity and increased the viability of STZ-induced β-cells in a dose-dependent manner. Allantoin decreases the level of caspase-3 and increases the level of phosphorylated B-cell lymphoma 2 (Bcl-2) expression. Allantoin has been demonstrated to activate imidazoline 3 (I3) receptors.

In Vivo:

The subchronic administration of allantoin (1, 3 or 10 mg/kg, for 7 days) significantly increases the latency time measured during the passive avoidance task in scopolamine-induced cholinergic blockade and normal naive mice. Allantoin treatment (3 or 10 mg/kg, for 7 days) also increases the expression levels of phosphorylated phosphatidylinositide 3-kinase (PI3K), phosphorylated protein kinase B (Akt) and phosphorylated glycogen synthase kinase-3β (GSK-3β). Allantoin significantly increases the neuronal cell proliferation of immature neurons in the hippocampal dentate gyrus region. Daily injection of allantoin for 8 days in STZ-treated rats significantly lowers plasma glucose and increases plasma insulin levels . Allantoin decreases blood pressures in SHRs at 30 minutes, as the most effective time. Also, this antihypertensive action is shown in a dose-dependent manner from SHRs treated with allantoin. Moreover, in anesthetized rats, allantoin inhibits cardiac contractility and heart rate. Also, the peripheral blood flow is markedly increased by allantoin.

Products are for research use only. Not for human use.